Actuate Therapeutics, Inc. (ACTU)

NASDAQ: ACTU · Real-Time Price · USD

10.13

+0.63 (6.63%)

May 2, 2025, 4:00 PM EDT - Market closed

Actuate Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	6.48	3.27	3.82
Research & Development	18.68	21.71	16.39
Operating Expenses	25.16	24.97	20.21
Operating Income	-25.16	-24.97	-20.21
Interest Expense	-0.02	-0.04	-0.02
Interest & Investment Income	0.22	0.35	0.03
Other Non Operating Income (Expenses)	-0.08	-0.08	0.04
EBT Excluding Unusual Items	-25.04	-24.74	-20.16
Other Unusual Items	-2.25	-	-
Pretax Income	-27.29	-24.74	-20.16
Net Income	-27.29	-24.74	-20.16
Net Income to Common	-27.29	-24.74	-20.16
Shares Outstanding (Basic)	8	1	1
Shares Outstanding (Diluted)	8	1	1
Shares Change (YoY)	483.48%	18.54%	-
EPS (Basic)	-3.26	-17.24	-16.65
EPS (Diluted)	-3.26	-17.24	-16.65
EBIT	-25.16	-24.97	-20.21

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q